Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
This Role Reflects the Company’s Commitment to Integrated Innovation Across Central Nervous System Disorders. Appointment Comes as Tris Prepares to Submit a New Drug Application (NDA) for...
-
– Encore data to be presented demonstrating that cebranopadol displays significant and sustained pain reduction with a distinguished safety profile following abdominoplasty and bunionectomy – –...
-
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate painIn both...
-
Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which uses a novel approach of activating NOP and MOP receptors to work synergistically to modulate...
-
– Preferential MOP agonists such as oxycodone are often required for effective management of moderate to severe pain but come with significant risks of addiction and overdose – – With Dual NMR...